Umbilical cord blood banking: economic and therapeutic challenges Online publication date: Thu, 03-May-2007
by Gregory Katz-Benichou
International Journal of Healthcare Technology and Management (IJHTM), Vol. 8, No. 5, 2007
Abstract: Since the first successful transplantation of umbilical cord blood in 1987, cord blood has become an important source of haematopoietic stem cells for the treatment of blood and genetic disorders. Important progress has been accompanied by challenges for scientists, ethicists and health policy-makers. With the increasing focus on cord blood as an alternative to human embryos and as a source of tissue for regenerative medicine, umbilical cord blood stem cells have attracted significant attention. In this paper, we review the therapeutic challenges and the competition between private and public cord blood banks, and also between cord blood inventories and bone marrow registries. We provide an international overview of banking activities, with a special focus on the French paradox. From access to bioresources to patent controversies, we analyse the economic impact of cord blood banking on health policies, and then discuss some ethical dilemmas of stem cell research.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Healthcare Technology and Management (IJHTM):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook